Compare BMBL & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | CADL |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.2M | 551.7M |
| IPO Year | 2021 | 2021 |
| Metric | BMBL | CADL |
|---|---|---|
| Price | $3.27 | $8.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $4.46 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $965,658,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $4.35 |
| 52 Week High | $8.63 | $9.26 |
| Indicator | BMBL | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 75.66 |
| Support Level | $2.68 | $4.80 |
| Resistance Level | $3.85 | N/A |
| Average True Range (ATR) | 0.26 | 0.55 |
| MACD | -0.12 | 0.17 |
| Stochastic Oscillator | 0.00 | 87.18 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.